#1B AstraZeneca H1 and Q2 2023 Results Conference call and webcast for investors and analysts 28 July 2023#22 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to our products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events such as the COVID-19 pandemic and the Russia-Ukraine war may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.#3H1 and Q2 2023 results Conference call agenda 3 CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks, Q&A Pascal Soriot Chief Executive Officer Aradhana Sarin Chief Financial Officer Dave Fredrickson EVP, Oncology Business Ruud Dobber EVP, BioPharmaceuticals Business Marc Dunoyer Chief Executive Officer, Alexion Pascal Soriot Chief Executive Officer Susan Galbraith EVP, Oncology R&D Mene Pangalos EVP, BioPharmaceuticals R&D B#4CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER#5Total Revenue | +4% H1 2022 Strong commercial performance and financial execution in H1 2023 +16% Ex-COVID-19 Total Revenue Benefitting from broad-based, diverse source of revenue H1 2023 CEO Opening Remarks Vaxzevria/COVID-19 mAbs¹ Total Revenue Core EPS +21% H1 2022 $4.07 Financial Results H1 2023 Oncology BioPharmaceuticals Oncology 39% Broad-based, diverse source of revenue Rare Disease H1 2023 % Total Revenue by therapy area R&I V&I Other 14% 3% 3% CVRM 24% H1 2023 % Total Revenue by geography US Europe 41% 20% CEO Closing Remarks Emerging Markets 28% All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 5 1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development. CER = constant exchange rates; EPS = earnings per share; CVRM = Cardiovascular, Renal & Metabolism; R&I= Respiratory & Immunology; V&I = Vaccines & Immune Therapies; EROW = Established Rest of World. Rare Disease 17% EROW 12% Reiterating 2023 guidance: Core EPS to increase by a high single-digit to low double-digit %#6Double-digit growth in US, Emerging Market, EU H1 Total Revenues (USD millions) and Growth vs PY +16% 9,081 US +22% Strong ex-COVID-19 growth across regions, disease areas Ex-China: 3,031 +38% China: 3,043 +9% Emerging Markets +13% CEO Opening Remarks 4,373 Europe +8% 2,450 Established Rest of World Financial Results 6 All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Total Revenue and growth rates by region reflect ex-COVID-19 figures. Oncology +22% 8,794 Double-digit growth across Oncology, CVRM, R&I and Rare disease H1 Total Revenues (USD millions) and Growth vs PY Oncology +20% BioPharmaceuticals 5,239 CVRM +10% Rare Disease 3,180 R&I +12% CEO Closing Remarks 3,819 Rare Disease -76% 632 V&I#7H1 2023 Performance Farxiga Imfinzi Ultomiris Enhertu Calquence Tagrisso Demand for multiple medicines driving H1 growth Breztri Tezspire Strensiq Fasenra Saphnelo Lokelma Koselugo Total Revenue USD million 2,834 1,976 1,364 580 1,185 2,915 307 135 562 744 115 198 159 Growth vs. PY USD million CEO Opening Remarks Financial Results 7 PY = prior year; CER = constant exchange rates; LCM = lifecycle management. Oncology BioPharmaceuticals Rare Disease 729 682 511 376 282 211 128 119 112 82 79 69 58 Growth vs. PY CER% 40% 57% 64% >2x 33% 12% 76% >8x 26% 14% >3x 59% 57% LCM strategy sustaining growth momentum, new launches accelerating globally CEO Closing Remarks#8CEO Opening Remarks Robust late-stage pipeline comprised of both LCM and NME opportunities >120 ongoing late-stage clinical trials across our pipeline 14 unique NMEs in late-stage development Leading late-stage pipeline, proven R&D execution Financial Results 10 potential blockbuster opportunities from 30 potential Phase III trials planned in 2023¹ Oncology BioPharmaceuticals Rare Disease Continued pipeline momentum with 8 positive pivotal trials in H1 2023 and catalyst-rich H2 2023 CEO Closing Remarks Tagrisso ADAURA OS (Adj EGFRm NSCLC) Imfinzi AEGEAN (Neoadj-adj NSCLC) Enhertu DESTINY-Pantumor02 (HER2 expressing tumours) Lynparza + Imfinzi + anti-VEGF + CTX DUO-O (ovarian) Tagrisso + CTX FLAURA2 (EGFRm NSCLC) Lynparza + Imfinzi + CTX DUO-E (endometrial) Imfinzi + FLOT MATTERHORN (Neoadj-adj gastric and GEJ) Dato-DXD TROPION-Lung01 (NSCLC) 1. Phase III trial start defined as first patient clinically dosed. R&D = Research & Development; siRNA = small interfering ribonucleic acid; NME = new molecular entity; OS = overall survival; EGFRm = epidermal growth factor receptor 8 mutant; NSCLC = non-small cell lung cancer; Neoadj-adj = neoadjuvant-adjuvant; HER2 = human epidermal growth factor receptor 2; anti-VEGF = anti-vascular endothelial growth factor; CTX = chemotherapy; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel; GEJ = gastroesophageal junction.#9Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 3#10Total Revenue H1 2023 - Reported profit and loss - Product Sales - Alliance Revenue - Collaboration Revenue Product Sales Gross margin Total operating expense¹ - R&D expense - SG&A expense Other operating income and expense Operating profit Tax rate CEO Opening Remarks Reported EPS H1 2023 $m 22,295 21,448 627 220 82.0% (14,588) (5,278) (9,045) 1,163 Financial Results 5,005 17% $2.34 CER change % 3 >2x (15) +13 pp 4 16 (2) >5x >4x >6x Oncology % Total Revenue 100 96 3 1 65 24 41 5 22 BioPharmaceuticals Q2 2023 $m 11,416 10,882 341 193 82.0% (7,784) (2,667) (4,986) 784 2,456 13% $1.17 Rare Disease CER change % 9 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of 10 Product Sales. 1. Total operating expenses include distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates. 5 >2x n/m +12 pp 8 7 8 >6x >6x >9x CEO Closing Remarks % Total Revenue 100 95 3 2 68 23 44 7 22 4#11Total Revenue H1 2023 - Core profit and loss - Product Sales - Alliance Revenue - Collaboration Revenue Product Sales Gross margin Total operating expense¹ R&D expense - SG&A expense Other operating income and expense Operating profit Tax rate CEO Opening Remarks Core EPS H1 2023 $m 22,295 21,448 627 220 82.9% (11,483) (4,868) (6,350) 1,102 Financial Results 8,237 18% $4.07 CER change % 4 3 >2x (15) +3 pp 8 9 8 >5x 20 21 Oncology % Total Revenue 100 96 3 1 52 22 28 5 сл 37 BioPharmaceuticals Q2 2023 $m 11,416 10,882 341 193 82.4% (5,995) (2,568) (3,296) 784 4,291 17% $2.15 Rare Disease CER change % 9 5 >2x n/m +2 pp 8 8 8 >6x 39 38 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 11 Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 1. Total operating expenses include distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates. CEO Closing Remarks % Total Revenue 100 95 3 2 53 22 29 7 38 A#12$bn 22.9 Net debt end 2022 $12.7bn 4.9 Cash Flow, Net Debt and 2023 Financial Guidance Continued EBITDA improvement CFO Net Debt bridge 0.5 Capex 2.4 3.1 Deal payments and receipts¹ Adjusted EBITDA². Dividend CEO Opening Remarks 0.1 Other 24.0 Net debt end June 2023 $14.2bn Financial Results Net Debt/EBITDA: 1.9x Net Debt/EBITDA adjusted for Alexion inventory fair value uplift: 1.7x ● Oncology ● BioPharmaceuticals Rare Disease ● Total Revenue Excluding COVID-19 medicines: low double-digit % growth Including COVID-19 medicines: low-to-mid single-digit % growth Reiterating 2023 Guidance (CER) Core EPS High single-digit to low double-digit % CEO Closing Remarks Expected FX-impact: Total Revenue: A low single-digit adverse impact Core EPS: Low to mid single-digit adverse impact³ Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1. Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. 2. EBITDA adding back the impact of $1,221m 12-month rolling period (FY 2022: $3,484m) unwind of inventory fair value uplift recognised on acquisition of Alexion. AstraZeneca credit 12 ratings: Moody's: short-term rating P-2, long-term rating A3, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. Assuming average June 2023 foreign exchange rates for July to December 2023. EBITDA = earnings before interest, tax, depreciation and amortisation; CFO = net cash inflow from operating activities; EPS = earnings per share.#13Drug development digital synthetic route design AI in Global Operations Leveraging the power of AI throughout our end-to-end supply chain in-silico models 50% reduction in route design lead time with Al-enabled predictive tools Solving for optimised routes with: CEO Opening Remarks Fewest synthetic steps Lowest potential COGS Lowest carbon footprint GLOBAL OPERATIONS | drug development, manufacturing and supply chain powered by Al Supply chain digital twins for raw material planning 13 1. In Gärtuna, Sweden. CMC - Chemistry, Manufacturing and Controls. Al = artificial intelligence; COGS = cost of goods sold. Financial Results Manufacturing advanced analytics and optimisation Identify new parameters >>>> O O Oncology <<<< <<<< >20% increased yield with Al-enabled analytic tools Target process adjustments BioPharmaceuticals Define new process ranges Rare Disease 1 | 2 90% reduction in dispensing planning time with Al-enabled digital twins CEO Closing Remarks balance material, asset, resource availability balance for various operations and products while ensuring "just-in-time" process#14Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R & D 50 12#15Total Revenue ($m) 5,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Oncology - H1 and Q2 2023 Total Revenue +22% in H1 2023 fuelled by demand growth and launch momentum Q3 2021 Oncology H1 2023 $8.8bn, +22% Q4 Q1 Q2 2022 Q3 Q4 Q1 2023 Q2 CEO Opening Remarks Tagrisso Imfinzi/Imjudo Calquence Enhertu Lynparza (PS) Lynparza milestones Others ● ● ● ● ● ● Financial Results ● Oncology BioPharmaceuticals Rare Disease Q2 2023: key dynamics CEO Closing Remarks Tagrisso +10%, strong global demand growth underpinned by ADAURA, slightly offset by NRDL price impact Lynparza PS +9%, double-digit growth in EU, EROW and EM, offset by flattening demand in 2L ovarian cancer in US Imfinzi +58%, driven by global launch acceleration (TOPAZ-1, HIMALAYA, POSEIDON) Calquence +34%, sustained BTKI class leadership Enhertu >2x, DB03/DB04 launch momentum, expanded reimbursement New indications: US (Lynparza PROpel BRCAm), CN (Enhertu DB04) capivasertib CAPItello-291 granted Priority Review in US All growth rates at CER. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza). 15 CER = constant exchange rates; NRDL= National Reimbursement Drug List; PS = Product Sales; EU = Europe; EROW= Established Rest of World; EM = Emerging Markets; BTKi = bruton tyrosine kinase inhibitor; BRCAm = breast cancer gene mutation; CN = China; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04. 4#16Imfinzi new launches continue to drive near-term growth HIMALAYA unresectable HCC TOPAZ-1 1L BTC POSEIDON 1L NSCLC Oncology - key Imfinzi opportunities in focus Strong launch uptake, robust LCM pipeline supporting continued IO leadership ● CEO Opening Remarks ● ● First dual 10 regimen Unprecedented 4-year OS data presented at ESMO World GI 2023 Financial Results First, innovative 10 regimen in BTC Established SoC in US within months EU, JP launch trajectory outpacing US Encouraging launch uptake in crowded competitive landscape New launch momentum (POSEIDON, HIMALAYA, TOPAZ) builds on top of sustained leadership in PACIFIC, CASPIAN H2 '23 Oncology H2 '23 BioPharmaceuticals Rare Disease LCM HLRs in 2023 contribute to sustained, mid-term Imfinzi growth AEGEAN (early resec. NSCLC) Significant improvement in EFS vs neoadjuvant CTx DUO-O (1L ovarian) Further improvement with Lynparza + Imfinzi CEO Closing Remarks DUO-E (1L endometrial) Greater benefit in Imfinzi + Lynparza + CTx arm MATTERHORN (Gastric and GEJ) First IO + FLOT to demonstrate clinical benefit PACIFIC-2 (Stg. III unresec. NSCLC) Potential to move 10 upfront + CCRT EMERALD-1 (locoregional HCC) Potential to improve PFS vs TACE therapy LCM = lifecycle management; 10 = immuno-oncology; HCC = hepatocellular carcinoma; OS = overall survival; ESMO = European Society of Medical Oncology; GI = gastrointestinal; GEJ = gastroesophageal junction; BTC = biliary tract cancer; SoC = 16 standard of care; JP = Japan; NSCLC = non-small cell lung cancer; HLR = high-level results; EFS = event-free survival; CTX = chemotherapy; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel; CCRT = concurrent chemoradiotherapy; PFS = progression free survival; TACE = transarterial chemoembolisation. 4#17CEO Opening Remarks P Oncology - R&D highlights Eight positive pivotal trial readouts so far this year ASCO highlights 2023 ADAURA final overall survival unprecedented survival in EGFRm NSCLC with 88% of patients alive on Tagrisso at 5 years Financial Results DUO-O interim analysis 37% reduction in risk of progression or death with Lynparza and Imfinzi added to chemotherapy and bevacizumab DESTINY-PanTumor02 interim analysis 37% ORR and 11.8 month mDoR with Enhertu across range of HER2-expressing solid tumours FLAURA2 R 1:1 R Oncology 1:1 DUO-E advanced endometrial cancer Platinum CTX + Imfinzi placebo Platinum CTX+ Imfinzi Platinum CTX+ Imfinzi R 1:1 1L EGFRm advanced NSCLC BioPharmaceuticals Tagrisso Tagrisso + carbo/cis + pemetrexed Placebo + FLOT Imfinzi + FLOT MATTERHORN resectable gastric and GEJ cancers SURGERY Rare Disease Placebo + FLOT Imfinzi + FLOT Presidential plenary WCLC) Imfinzi placebo + Lynparza placebo Imfinzi + Lynparza placebo Imfinzi + Lynparza CEO Closing Remarks Tagrisso Tagrisso + pemetrexed ASCO = American Society of Clinical Oncology; EGFRm = epidermal growth factor receptor mutated; NSCLC = non-small cell lung cancer; ORR = objective response rate; mDoR = median duration of response; HER2 = human epidermal 17 growth factor receptor 2; 1L = 1st-line; R = randomise; carbo/cis = carboplatin/cisplatin; CTX = chemotherapy; GEJ = gastroesophageal junction; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel. Collaboration partners: Daiichi Sankyo (Enhertu) Placebo Imfinzi#18TROPION-Lung01 Dato-DXd in 2-3L advanced NSCLC Statistically significant PFS benefit Favourable early OS trend All grade ILD consistent with previous Dato-DXd trials Oncology - R&D highlights TROPION-Lung01 reinforces importance of Dato-DXd in NSCLC and beyond Some Grade 5 ILD cases observed No new safety signals CEO Opening Remarks Proceeding to file data with FDA Lung cancer Breast cancer Financial Results Other tumours Replace CTX as monotherapy TROPION-Lung01 2-3L NSCLC w/ and w/o AGAS TROPION-Lung05 2L+ NSCLC w/ AGA TROPION-Breast01 2L+ HR+ HER2- mBC TROPION-Breast02 1L PD-L1- aTNBC¹ Oncology TROPION-PanTumor01 advanced solid tumours BioPharmaceuticals H2 Further outcomes with novel combinations TROPION-Lung02 + pembro + platinum CTX | 1-3L NSCLC w/o AGAS TROPION-Lung04 + Imfinzi / rilvegostomig / volrustomig + carbo | 1-2L NSCLC w/o AGAS TROPION-Lung07 + pembro + platinum CTX | 1L PD-L1<50% NSCLC w/o AGAS TROPION-Lung08 + pembro | 1L PD-L1250% NSCLC w/o AGAS ORCHARD + Tagrisso | EGFRm 2L NSCLC Rare Disease BEGONIA + Imfinzi | 1L a TNBC TROPION-Breast03 + Imfinzi | adjuvant eTNBC TROPION-PanTumor03 +/- combinations | advanced solid tumours AVANZAR + Imfinzi + carbo | 1L NSCLC w/o AGAS Assess predictive value of TROP2 biomarker CEO Closing Remarks Solid colour indicates Phase III trial; outline only indicates Phase I or II trial. Lung studies in the locally advanced / metastatic setting. 1. or not candidate for PD-(L)1 therapy for another reason. Dato-DXd = datopotamab deruxtecan; NSCLC = non-small cell lung cancer; PFS = progression free survival; OS = overall survival; ILD = interstitial lung disease; FDA = US Food and Drug Administration; AGA = actionable genomic alterations; pembro = pembrolizumab; CTx = chemotherapy; carbo = carboplatin; PD-L1 = programmed cell death ligand 1; EGFRm = epidermal growth factor receptor mutation; 18 mBC = metastatic breast cancer; HR+ = hormone receptor positive; HER2- = human epidermal growth factor receptor negative; aTNBC = advanced triple negative breast cancer; eTNBC = early triple negative breast cancer. Collaboration partners: Daiichi Sankyo (Dato-DXd)#19BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Mene Pangalos BIOPHARMACEUTICALS R&D O WABU n 00#20Total Revenue ($m) Q2 dynamics BioPharmaceuticals - H1 and Q2 2023 Double digit growth from CVRM and R&I 3,000 2,500 2,000 1,500 1,000 500 ● 0 Q3 CVRM H1 2023 $5.2bn, +20% Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 2022 Farxiga Brilinta Lokelma Others Farxiga +41%, to $1.5bn Lokelma, roxadustat and Andexxa, strong double-digit growth 2023 Total Revenue ($m) CEO Opening Remarks Q2 dynamics 1,800 1,600 1,400 1,200 1,000 800 600 400 200 0 Q3 Financial Results R&I H1 2023 $3.2bn, +10% Q4 Oncology Q1 Q2 Q3 Q4 Q1 Q2 2021 Symbicort Pulmicort Fasenra Breztri Tezspire Saphnelo Others 2022 Fasenra +16%, to $406m Breztri +79%, to $163m Tezspire +50%, sequential QoQ growth 2023 Total Revenue ($m) Q2 dynamics BioPharmaceuticals 2,500 2,000 1,500 1,000 ● ● ● 500 0 Q3 V&I H1 2023 $632m, -76% Rare Disease Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 CEO Closing Remarks 2022 2023 COVID-19 mAbs¹ Vaxzevria Synagis FluMist Beyfortus All growth rates at CER. 1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development 20 CER = constant exchange rates; CVRM = Cardiovascular, Renal and Metabolism; R&I = Respiratory and Immunology; QoQ = quarter on quarter; V&I= Vaccine and Immune Therapies; mAbs = monoclonal antibodies. Collaboration partners: Amgen (Tezspire); Sanofi (Beyfortus). COVID-19 medicines declined by $0.7bn FluMist $10m, milestone for Japan approval Beyfortus, first Product Sales#21Europe Diverse source of Total Revenues EROW H1 2023 Total Revenue US CEO Opening Remarks Farxiga - - strategic development Redefined outcomes for patients, clear evidence of AstraZeneca's core strength in CVRM Emerging Markets Financial Results Heart failure Growth driven by HF and CKD¹ Type-2 diabetes Oncology Split of Farxiga new patient share Chronic kidney disease BioPharmaceuticals Rare Disease Others Farxiga SGLT2i class leadership² CEO Closing Remarks SGLT2i share (days of treatment) Phased LOE with a late-stage pipeline to sustain therapy area leadership Farxiga 1.AstraZeneca internal estimates. 2. Based on internal analysis by AstraZeneca UK Limited using data from IQVIA MIDAS® SU volume data for the period Q1 2023, covering 55 countries and reflecting estimates of real-world activity. Copyright IQVIA. All rights 21 reserved. DOT calculated based on AstraZeneca dosing assumptions CVRM = cardiovascular, renal and metabolism; HF = heart failure; CKD = chronic kidney disease; SGLT2i = sodium/glucose cotransporter-2 inhibitor; LOE = loss of exclusivity. 4#22tozorakimab Severe viral lung infection Airway epithelium Airway endothelium Staining showed localised IL-33 in airway IL-33red/sST2 levels associated with poor clinical outcomes ST2 expressed in alveolar capillary cells ATS BioPharmaceuticals - R&D highlights ATS and ERA data highlights improvement in patient outcomes across R&I and CVRM Clear rationale for targeting IL-33 in severe viral lung infection CEO Opening Remarks Post-index COPD Exacerbations 2.50 2.00 1.50 EROS: relationship between timing of Breztri initiation and exacerbation rate 1.00 Initiating <30 days resulted in 24% reduction in the risk of future exacerbations vs delaying treatment up to six months 2.30 0.50 0.00 Financial Results Breztri Real-world evidence 2.00 1.52 Any exacerbation 1.46 Oncology 1.93 2.14 ATS Moderate exacerbation Prompt initiation¹ Delayed initiation Very delayed initiation 0.060.080.16 Severe exacerbation Exacerbation risk increased by 5% every month Breztri treatment was delayed ● BioPharmaceuticals ● Rare Disease CEO Closing Remarks Farxiga and Lokelma CERA LEADING EUROPEAN NEPHROLOGY Real-world evidence and guideline updates REVEAL-CKD: 85-97% Stage 3 CKD undiagnosed² Delaying diagnosis of CKD by one year: risk of deterioration by 40% risk of kidney transplant/long-term dialysis treatment by 63% ZORA highlighted role of Lokelma for patients with HK whilst on RAASI CKD and HF guidelines³ recommend and support use of K+ binders Highlights importance of early diagnosis and concomitant K+ use in RAASI therapy 1. Prompt initiation initiated therapy ≤30 days, Delayed initiation initiated therapy >30 - <180 days, Very delayed initiation initiated therapy 180 days. 2. REVEAL-CKD multinational study, data referenced includes Spain, Australia, Canada and Brazil. 3. Guidelines include: KDIGO (HTN in CKD and Diabetic Kidney), ESC (HF), AHA/ACC/HFSA (HF) 22 ATS = American Thoracic Society; ERA = European Renal Association; R&I = Respiratory & Immunology; CVRM = Cardiovascular, Renal & Metabolism; IL-33= interleukin-33; red= reduced form; SST2 = soluble serum stimulated-2; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease, HK = hyperkalaemia; RAASI = renin-angiotensin-aldosterone system inhibitor; HF = heart failure; K+ = potassium.#23Oligonucleotides eplontersen (TTR ASO), ATTRv-PN/CM - Phase III AZD2693 (PNPLA3 ASO), NASH - Phase llb BioPharmaceuticals - novel platforms Disruptive biology to access next-generation therapeutics AZD7503 (HSD17B13 LICA), NASH - Phase I AZD2373 (APOL1 ASO), CKD - Phase I Advanced biologics MEDI7352 (NGF/TNF), pain - Phase II CEO Opening Remarks AZD8630 (ITSLP), asthma - Phase I Financial Results Cell therapy Procella -HF¹ THERAPEUTICS Oncology - CAR-Treg Quellx (T1D and IBD) BioPharmaceuticals RNA therapies mRNA sa RNA CRNA Rare Disease quide RNA WILT CEO Closing Remarks PROLECE ITLENTE Marching Hours CASO Gene therapy Familial hyper- cholesterolaemia (LDLR) Duchenne musculo- dystrophy (dystrophin) 1. Poch, C.M., Foo, K.S., De Angelis, M.T. et al. Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors. Nat Cell Biol 24, 659-671 (2022). https://doi.org/10.1038/s41556-022-00899-8. HF = heart failure; Treg = T-regulator cell therapies; T1D = Type I Diabetes, IBD = Inflammatory Bowel Disease; TTR = transthyretin; ASO = antisense oligonucleotide; ATTR = transthyretin-mediated amyloid, PN = polyneuropathy, CM = cardiomyopathy; 23 PNPLA3 = patatin like phospholipase domain containing 3; NASH = non-alcoholic steatohepatitis; LICA = ligand-conjugated antisense; APOL1 = apolipoprotein L1; CKD = chronic kidney disease; LDLR = low density lipoprotein receptor; HTT= huntingtin; mRNA = messenger ribonucleic acid; saRNA = small activating ribonucleic acid; CRNA = complementary ribonucleic acid; inhaled thymic stromal lymphopoietin; NGF/TNF = nerve growth factor/tumour necrosis factor-alpha. Huntington's disease (HTT)#24Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 3#25Total Revenue ($m) 2,500 Rare Disease - H1 and Q2 2023 Continued expansion in neurology, growth beyond complement 2,000 1,500 1,000 500 0 Q3 2 2021 Q4 Rare Disease H1 2023 $3.8bn, +12% Q1 Q2 2022 Q3 Ultomiris Soliris Strensiq Others¹ Q4 Q1 2023 CEO Opening Remarks Q2 Financial Results Oncology BioPharmaceuticals Rare Disease Q2 2023: key dynamics CEO Closing Remarks Continued strength of C5 Franchise Ultomiris +66%, driven by growth in neurology, expansion into new markets and successful conversion from Soliris All growth rates at CER. 1. Includes Kanuma and Koselugo. 2. Q3 2021 Total Revenues reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021. 25 C5 C5 inhibitors Ultomiris and Soliris; CER = constant exchange rates; NMOSD = neuromyelitis optica spectrum disorder. Collaboration partners: Merck & Co., Inc. (Koselugo). Soliris (19%), decline reflecting conversion partially offset by NMOSD growth Strensiq, +25% and Koselugo, +30% Reflecting continued strength of patient demand and expansion into new markets#26Rare Disease - R&D highlights Accelerating in ALXN2220 to Phase III for ATTR-CM ALXN2220 (NI006) | mAb IgG1 Phase Ib¹ in ATTR-CM CEO Opening Remarks H/WB ratio Total N1006 clearance of cardiac amyloid shown at 4 and 12 months Representative images from scintigraphy after treatment with ALXN2220 A Patient 1, 75yo male, ATTRwt, 60 mg/kg N1006 Baseline 6.9% 4 months 2.5% 20.7 g (46.1 d* mg/ml) Financial Results NI006 improvement in cardiac function (NT-proBNP) ESC European Society of Cardiology + 12 months 2.5% 61.7 g (162.7 d*mg/mL) EDICINE 1551 2010 1856 potential monthly i.v. dosing Selectively binds and removes misfolded amyloid fibrils Oncology 1 2 3 BioPharmaceuticals pathophysiology Complimentary mechanisms transforming ATTR-CM TTR production in the liver Tetramer formation Organ deposition Rare Disease ПО ∞ CEO Closing Remarks 1. Garcia-Pavia et al. NEJM Phase 1 Trial of Antibody ALXN2220 (N1006) for Depletion of Cardiac Transthyretin Amyloid. Representative images from serial bisphosphonate scintigraphy from one patient randomly assigned to receive ALXN2220 (N1006). 2. Alexion, AstraZeneca Rare Disease has the Japanese rights to acoramidis. ATTR-CM = transthyretin amyloid cardiomyopathy; mAb = monoclonal antibody; IgG1 = immunoglobulin G1; yo = year-old; wt = wild- 26 type; H/WB = heart-to-whole body ratio; TTR = transthyretin. Collaboration partner: Neurimmune; lonis; Bridge Bio. medicine and modality Silencer eplontersen blocks TTR synthesis Stabiliser acoramidis² stabilises TTR tetramers Depleter ALXN2220 binds to misfolded TTR, removes toxic fibrils#27Liver, kidney Heart, muscle Rare Disease - R&D highlights Innovative delivery platforms expanding genomic research CNS + gene editing SAAVY™ ‒‒‒‒‒‒‒‒‒‒ AAV THERAPEUTICS Y protein TfR1 conjugate delivery JU (JCR Pharmaceuticals CEO Opening Remarks Azt + CRISPR non-viral oligo- nucleotide non-viral Financial Results AAV + CRISPR Oncology ALXN2030 non-viral (C3 siRNA) AAV 2Pfizer AAV CRISPR +LNP BioPharmaceuticals + AAV Pfizer AAV Rare Disease Furthering our genomic capabilities CEO Closing Remarks accelerating genomic portfolio ambitions with acquisition of Pfizer AAV capsids combining innovative technologies with LogicBio and AstraZeneca partnering to access novel gene delivery technology Acquisitions and collaborations complement existing AstraZeneca technologies and increases genomic medicine portfolio >4x SAAVYTM = proprietary adeno-associated virus capsid engineering platform; CRISPR = clustered regularly interspaced short palindromic repeats; C3 = complement protein 3; siRNA = short interfering RNA; LNP = lipid nanoparticle; 27 AAV = adeno-associated virus; CNS = central nervous system; TfR1 = transferrin receptor protein 1. Note: Acquisition of Pfizer preclinical gene therapy programmes subject to customary regulatory clearances and other closing conditions.#28CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER#29Scope 1 & 2 Decarbonisation through pioneering partnership with Vanguard Renewables Enabling the delivery of renewable natural gas to all US sites by 2026¹ to save: Progressing Ambition Zero Carbon Taking bold action to mitigate climate change through new and expanded initiatives AMBITION ZERO CARBON | on track to deliver absolute reductions in GHG emissions across our value chain 650,000m British thermal units per year 35kt GHG emissions per year AstraZeneca Vanguard CEO Opening Remarks RENEWABLES Scope 3 Financial Results to: Oncology Investing $400m to plant and maintain 200 million trees by 2030 AZ Forest expanding our global reforestation and biodiversity initiative BioPharmaceuticals restore biodiversity build on existing forest projects maximise environmental and community co-benefits sequester carbon Scopes 1, 2, 3 Rare Disease Major initiatives Residual emissions removal Making progress towards our SBTi approved targets² Transition plan focused on major decarbonisation initiatives and residual emissions removal Scope 1 & 2 site efficiency renewable power/heat electric vehicle management of F-gas <2% using bioenergy with carbon capture and storage CEO Closing Remarks 1. By end of 2026. 2. Our net zero scope 1-3 science-based targets have been verified under the Science Based Targets initiative Net-Zero Corporate Standard; reduce our greenhouse gas emissions from our global operations and 29 fleet (Scope 1 and 2) by 98% by early 2026, from 2015 baseline. Reduce our greenhouse gas emissions across our entire value chain footprint (Scope 1, 2 and 3) by 50% by 2030, a 90% reduction by 2045, from 2019 baseline. 3. From 2030. GHG = greenhouse gases; kt = kilo-tonnes; SBTi = science-based targets initiative; NGP = next-generation propellant. - Scope 3 supplier engagement NGP sustainable product design nature-based solutions³, including AZ Forest#30capivasertib CAPItello-290 (1L mTNBC) Extend beyond PIK3/AKT/PTEN alterations in unselected population Robust Phase III catalysts in H2 2023 Key trial readouts reinforce transformative pipeline potential Imfinzi PACIFIC-2 (Stg. III unresec. NSCLC) Potential to move 10 upfront + CCRT Fasenra MANDARA (EGPA) CEO Opening Remarks Reinforcing first-choice biologic in eosinophil driven diseases Imfinzi EMERALD-1 (loco-regional HCC) Financial Results Potential to improve PFS vs TACE therapy Dato-DXd TROPION-Breast01 (2L+ HR+/HER2- mBC) Oncology Building on TNBC efficacy, expanding into HR+/HER2- mBC (c.70% mBC subtypes) AZD3152 SUPERNOVA immuno-bridging sub-study (COVID-19 prevention) Next-gen prophylactic LAAB for immunocompromised (c.2% population) BioPharmaceuticals KI XX Rare Disease CEO Closing Remarks Total Revenue ambition¹: low double-digit % 2021-2025 Industry-leading growth 2025+ Remain focused on Operating Margin expansion At least 15 NMES approved by 2030 Emissions reduction: 98% by end 2025 - Scope 1 & 2 50% by 2030 - Scope 3 Confident in leading growth profile: base business strength with innovative late-stage pipeline 1. Indicates Company ambition to achieve Total Revenue low double-digit CAGR through 2025 (2021 base year, Alexion pro-forma) and industry-leading Total Revenue beyond 2025; this is not formal guidance. 1L = 1st-line; mTNBC = metastatic triple negative breast cancer; PIK3/AKT/PTEN = phosphatidylinositol-3 kinase/protein kinase B/phosphatase and tensin homolog; EGPA = eosinophilic granulomatosis with polyangiitis; 2L+ = 2nd-line plus; HR+ = hormone receptor positive; HER2- = human 30 epidermal growth factor receptor 2 negative; mBC = metastatic breast cancer; Stg. = stage; unrecec. = unresectable; NSCLC = non-small cell lung cancer; CCRT = concurrent chemoradiation therapy; HCC = hepatocellular carcinoma; PFS = progression- free survival; TACE = trans arterial chemoembolisation; LAAB = long-acting antibody; NME = new molecular entity.#31CEO Opening Remarks 31 Financial Results Mene Pangalos to retire after almost 14 years with AstraZeneca Oncology BioPharmaceuticals R&D leadership change BioPharmaceuticals Sharon Barr to assume role of EVP, BioPharmaceuticals R&D Rare Disease CEO Closing Remarks#3232 Question & Answer Session Pascal Soriot EXECUTIVE DIRECTOR & CHIEF EXECUTIVE OFFICER Susan Galbraith EXECUTIVE VICE PRESIDENT, ONCOLOGY R&D Ruud Dobber EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS BUSINESS Aradhana Sarin EXECUTIVE DIRECTOR & CHIEF FINANCIAL OFFICER Dave Fredrickson EXECUTIVE VICE PRESIDENT, ONCOLOGY BUSINESS Iskra Reic EXECUTIVE VICE PRESIDENT, VACCINES AND IMMUNE THERAPIES Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION Mene Pangalos EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS R&D Leon Wang EXECUTIVE VICE PRESIDENT, INTERNATIONAL B#33Appendix ■ ■ ■ ■ Pipeline Highlights Oncology tumour maps Emerging Markets performance Key medicines performance by therapy area#34Delivering on science-led Selected key pipeline highlights since Q1 2023 results innovation 10 regulatory approvals in major markets, including: Lynparza (US) prostate cancer (1st-line) (PROpel) Enhertu (CN) HER2-low breast cancer (3rd-line) Farxiga (US) HFPEF (DELIVER) Beyfortus (US) RSV (MELODY/MEDLEY) Xigduo (CN) type-2 diabetes (XR formulation) APPENDIX | Pipeline Highlights Oncology BioPharmaceuticals Rare Disease Soliris (EU) generalised myasthenia gravis (refractory, children and adolescents) Soliris (CN) generalised myasthenia gravis Ultomiris (EU, JP) neuromyelitis opticaspectrum disorder (CHAMPION-NMO) Koselugo (CN) neurofibromatosis type-1 with plexiform neurofibromas (SPRINT) 34 HER2-low = human epidermal growth factor receptor 2-low; HFpEF = heart failure with preserved ejection fraction; RSV = respiratory syncytial virus; XR = extended release; CHMP = Committee for Medicinal Products for Human Use. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza, Koselugo), Sanofi (Beyfortus). A#35AstraZeneca in Lung Cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 Est. epi (G7) 10 sensitive c.70% EGFRm c.16% Other tumor drivers c.12% HER2 c.2% resectable Stg. I-III ~200K Imfinzi AEGEAN volrustomig + CTX NEOCOAST-2 Tagrisso ADAURA Tagrisso neo-ADAURA established SoC unresectable Stg. 1-11 ~30K Imfinzi w/ SBRT PACIFIC-4 Stg. III ~70K CRT → Imfinzi PACIFIC CRT + Imfinzi PACIFIC-2 Imfinzi combos PACIFIC-8, -9 improvements across PD-L1 spectrum CRT → Tagrisso LAURA CRT → Imfinzi PACIFIC 1L ~350K Imfinzi + Imjudo + CTx POSEIDON Dato-DXd + 10 rilvegostomig (PD1/TIGIT) ARTEMIDE-1 TROPION-Lung08 AVANZAR TROPION-Lung07 TROPION-Lung04/02 Enhertu + 10 DESTINY-Lung03 Tagrisso FLAURA Tagrisso + CTx FLAURA2 metastatic Enhertu DESTINY-Lung04 volrustomig (PD1/CTLA4) 2L+ ~290K Imfinzi + ceralasertib LATIFY Dato-DXd TROPION-Lung01 AZD9592 (EGFR/CMET ADC) EGRET sabestomig (PD1/TIM3) savolitinib + Tagrisso SAFFRON/SAVANNAH AZD9592 (EGFR/CMET ADC) EGRET Dato-DXd TROPION-Lung01 TROPION-Lung05 Enhertu DESTINY-Lung02 APPENDIX | Oncology tumour maps ● Leading the future of lung cancer treatment Tagrisso established TKI backbone in EGFRm Imfinzi leading 10 in unresectable Advancing best-in-class ADCs to replace systemic chemotherapy Delivering next-wave bispecifics to improve on PD1/PD-L1 Developing novel combinations, including 10 + ADC Investing behind new technologies and platforms, including cell therapy, testing/screening Est epi (G7) = estimated epidemiology across G7 (US, EU5, JP); Stg. = stage; CTx = chemotherapy; SBRT = stereotactic body radiation therapy; CRT = chemoradiotherapy; pembro = pembrolizumab; 10 = immunotherapy; ADC = antibody-drug conjugate; PD1 = programmed cell death protein 1; EGFR = epidermal growth factor receptor; c-MET = mesenchymal-epithelial transition factor; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains; CTLA4 = cytotoxic T-lymphocyte associated protein 4; 35 TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; SoC = standard of care; TKI = tyrosine kinase inhibitor. B Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig).#36AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death established SoC Est. epi (G7) HER2-positive 15-20% HR-positive 65-75% HER2-low 60% TNBC 10-15% === HER2-low 35% gBRCAm 5% of HR-positive 15% of TNBC Neoadjuvant Enhertu +/- THP DESTINY-Breast11 Early 540k Adjuvant NST→ residual disease → Enhertu DESTINY-Breast05 Low risk Current SoC drives good outcomes for patients with low risk HR-positive eBC CTX AI (+/- CDK4/6i) → camizestrant CAMBRIA-1 NST → residual disease → Dato-DXd +/- Imfinzi TROPION-Breast03 CTX→ Lynparza OlympiA RECRURENCE ESR1m PD-L1- 60% 1st line 125k Enhertu DESTINY-Breast09 camizestrant + CDK4/6i SERENA-4 CDK4/6i + AI → CDK4/6i + camizestrant SERENA-6 capivasertib + Faslodex + CDK4/6i CAPItello292 capivasertib + paclitaxel CAPItello290 Dato-DXd TROPION-Breast02 HER2-low Metastatic 2nd line HER2 90k Enhertu DESTINY-Breast03 capivasertib + Faslodex CAPItello291 Enhertu DESTINY-Breast06 Lynparza OlympiAD HER2-low APPENDIX | Oncology tumour maps 3rd line 65k 4th line + Enhertu DESTINY-Breast02 55k Dato-DXd TROPION-Breast01 Enhertu DESTINY-Breast04 All numbers are approximate. Illustrative settings and populations, not to scale. 1/2/3/4L = 1st/2nd/3rd/4th-line; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients. HER2 = human epidermal growth factor receptor 2; THP = docetaxel, trastuzumab, and pertuzumab;NST = neoadjuvant systemic treatment; HR = hormone receptor; SoC = standard of care; CTXx = chemotherapy; Al = aromatase inhibitor; CDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor; ESR1m = oestrogen receptor 1 gene mutation; Dato-DXd = datopotamab deruxtecan; TNBC = triple negative breast cancer; PD-L1 = programmed cell death ligand 1; gBRCAm = germline BRCA-mutated. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Merck & Co., Inc. (Lynparza).#37Emerging Markets - H1 2023 Total Revenue +9% at CER to $6.3bn, +22% at CER ex-COVID-19 medicines Total Revenue ($m) 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Q2 Q3 2021 Q4 China Emerging Markets ex-China COVID-19 medicines Q1 37 Growth at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets. Q2 2022 Q3 Q4 Q1 APPENDIX | Emerging Markets 2023 Q2 B#38Oncology Total Revenue ($m) 1,600 1,400 1,200 1,000 800 600 400 200 ☐EM 0 EROW ■ Europe ■US Q2 390 234 244 438 Tagrisso 12% growth at CER to $2,915m in H1 2023 Q3 2021 315 232 259 441 Q4 325 245 258 486 Q1 406 207 252 439 Q2 400 231 256 513 2022 Q3 406 203 268 521 Q4 356 206 245 535 38 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Q1 444 202 257 521 2023 Q2 408 218 284 581 Total Revenue ($m) 1,200 1,000 800 600 400 200 ☐EM 0 EROW Europe US Q2 75 106 118 305 Imfinzi 57% growth at CER to $1,976m in H1 2023 Q3 2021 78 101 120 319 Q4 65 101 138 330 Q1 58 101 125 315 Q2 APPENDIX | H1 2023 Product Performance 75 104 142 374 2022 Q3 90 99 135 413 Q4 63 97 142 450 Q1 81 134 163 522 2023 Q2 102 222 176 576#39Oncology Product Sales ($m) 800 700 600 500 400 300 200 100 ☐EM 0 EROW ■ Europe US Q2 99 67 153 269 Lynparza 10% growth at CER to $1,368m in H1 2023 Q3 2021 96 67 155 270 Q4 103 71 161 294 Q1 121 66 160 270 Q2 120 72 169 312 2022 Q3 117 64 164 314 Q4 130 66 162 331 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 39 CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Collaboration partners: Merck & Co., Inc. (Lynparza). Q1 137 68 178 268 2023 Q2 142 77 187 311 Lynparza Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential Collaboration Revenue ($m) 600 400 200 0 Sales Milestone Regulatory Milestone Q2 Q3 2021 Q4 400 Q1 APPENDIX | H1 2023 Product Performance 175 Q2 2022 Q3 75 Q4 105 Q1 2023 Q2 3#40Oncology Total Revenue ($m) 700 600 500 400 300 200 100 0 ■EM ☐EROW ■ Europe US Q2 5 3 22 250 Calquence 33% growth at CER to $1,185m in H1 2023 Q3 2021 5 4 37 308 Q4 8 8 43 336 Q1 1353 7 55 339 Q2 8 18 67 396 2022 Q3 12 18 79 457 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 40 CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Collaboration partners: Daiichi Sankyo (Enhertu). Q4 17 20 86 465 Q1 18 22 108 384 2023 Q2 24 27 117 485 Total Revenue ($m) 350 300 250 200 150 100 50 0 ☐EM ☐EROW Europe US Q2 3 6 40 Enhertu >2x growth at CER to $580m in H1 2023 Q3 2021 4 9 45 Q4 5 13 49 Q1 9 1 20 57 Q2 APPENDIX | H1 2023 Product Performance 17 2 26 73 2022 Q3 25 2 31 124 Q4 29 3 33 151 Q1 38 3 55 161 2023 Q2 69 5 70 178#41BioPharmaceuticals: Cardiovascular, Renal & Metabolism Total Revenue ($m) Farxiga 40% growth at CER to $2,834m in H1 2023 1,600 1,400 1,200 1,000 800 600 400 200 ΠΕΜ 0 Q3 2021 297 320 318 391 423 68 63 78 99 98 213 225 318 309 329 171 202 228 193 275 279 Q2 Q4 Q1 EROW Europe 198 US Q2 Q3 Q4 2022 410 441 84 72 Q1 Q2 2023 498 578 138 136 342 393 456 323 296 339 Total Revenue ($m) 400 41 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. 350 300 250 200 150 100 50 0 ☐EM ■EROW ■ Europe ■US Brilinta 1% growth at CER to $665m in H1 2023 Q2 74 17 90 194 Q3 2021 76 71 69 16 16 14 85 83 76 198 178 166 Q4 Q1 Q2 Q3 2022 78 76 14 10 73 65 185 187 Q4 Q1 Q2 2023 64 82 8 6 67 67 206 179 79 6 68 178 Total Revenue ($m) 120 100 80 60 40 20 ☐EM 0 Lokelma 59% growth at CER to $198m in H1 2023 EROW ■ Europe ■US APPENDIX | H1 2023 Product Performance Q2 1 10 3 25 Q3 Q4 2021 1 13 3 32 15 5 34 Q1 3 15 6 39 Q2 Q3 Q4 Q1 2022 2 18 7 39 9 17 8 45 6 18 9 48 Q2 2023 11 13 20 24 11 14 56 49#42BioPharmaceuticals: Respiratory & Immunology Total Revenue ($m) 450 400 350 300 250 200 150 100 50 ΠΕΜ 0 Fasenra 14% growth at CER to $744m in H1 2023 EROW ■ Europe US Q2 Q3 Q4 Q1 Q2 1.1.1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2021 14 15 22 6 8 7 2 3 5 25 47 53 Q3 2022 2021 5 7 5 7 10 12 41 41 43 37 36 35 73 75 75 75 78 77 201 199 234 189 230 229 Q4 Q1 Q2 2023 13. 14 14 35 35 36 76 88 89 257 201 267 180 160 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 42 CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Collaboration partners: Amgen (Tezspire). 140 120 100 80 60 40 20 0 ☐EM ■EROW Breztri 76% growth at CER to $307m in H1 2023 ■ Europe ■US 17 7 1 31 2022 21 10 9 53 28 21 9 9 8 11 58 75 2023 38 10 15 81 43 15 21 84 90 80 70 60 50 40 30 20 10 0 Tezspire >8x growth at CER to $135m in H1 2023 APPENDIX | H1 2023 Product Performance ☐EM EROW ■ Europe US Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 T 1 1 1 1 i 2022 - 3 13 26 2 2 37 Q2 2023 4 7 43 8 11 62 B#43BioPharmaceuticals: Respiratory & Immunology Total Revenue ($m) 800 700 600 500 400 300 200 100 ☐EM 0 EROW ■ Europe US Q2 141 99 176 264 Symbicort 4% growth at CER to $1,288m in H1 2023 Q3 2021 151 96 155 274 Q4 152 96 171 262 Q1 167 91 157 259 Q2 139 98 155 222 2022 Q3 169 91 133 237 Q4 133 95 137 255 43 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Q1 229 79 147 233 2023 Q2 177 86 137 200 Total Revenue ($m) 300 250 200 150 100 50 0 ☐EM ☐EROW Europe US Q2 119 12 18 18 Pulmicort 11% growth at CER to $346m in H1 2023 Q3 2021 173 12 15 17 Q4 193 13 23 19 Q1 164 13 18 22 APPENDIX | H1 2023 Product Performance Q2 72 12 17 15 2022 Q3 103 12 14 16 Q4 123 12 19 12 Q1 182 9 20 10 2023 Q2 90 11 16 7#44Rare Disease Total Revenue ($m) Soliris 16% decrease at CER to $1,648m in H1 2023 1,200 1,000 800 600 400 200 ☐EM 0 EROW ■ Europe ■US Q2 Q3 2021 53 117 71 86 111 107 174 199 240 221 460 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2022 2023 99 63 84 83 115 104 91 88 86 216 190 179 183 184 608 591 574 523 491 448 445 Total Revenue ($m) Ultomiris 64% growth at CER to $1,364m in H1 2023 800 700 600 500 400 300 200 100 0 ■ EM EROW ■ Europe ■US Q2 a L - Q3 2021 5 56 69 167 214 220 Q4 Q1 Q2 Q3 Q4 2022 4 24 6 73 70 72 100 105 120 236 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 44 Q3 2021 Total Revenue shows the numbers reported by AstraZeneca following the acquisition of Alexion, which completed on 21 July 2021. CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World. Q1 Q2 2023 4 4 77 90 122 134 315 365 381 13 17 98 110 159 152 434 Total Revenue ($m) 350 300 250 200 150 100 50 0 Strensiq 26% growth at CER to $562m in H1 2023 EM EROW ■ Europe ■US Q2 APPENDIX | H1 2023 Product Performance Q3 Q4 2021 st 4 6 15 20 16 20 124 173 Q1 9 19 19 161 Q2 1000 Q3 Q4 2022 Q1 Q2 2023 9 8 10 15 19 19 19 21 21 18 19 193 192 224 205 9 22 21 21 248